Lupin launches Methergine brand in US; drugmaker markets five brands in this market

MUMBAI: Lupin is bolstering its US branded drugs portfolio with the introduction of Methergine, an oral tablet used to treat postpartum haemorrhage, in the US market.

The company said it has put significant investment in professional education in promoting the drug, which it hoped can be used to handle the rising incidences of maternal deaths that are caused by excessive bleeding.

Lupin’s latest launch and investments in the product points to a growing trend of Indian companies to seek revenues from branded drugs. The US is Lupin’s largest market and contributed 45% to the company’s $2.06 billion revenue in FY2015.

Lupin ventured into branded specialty products much ahead of its Indian peers with its antibiotic Suprax after securing exclusive rights for the US. Lupin markets five brands in the US. “The company is committed to strengthen its branded and specialty portfolio through alliances as well as developing its own pipeline and making strategic brand acquisitions,” the company said.